MedPath

Clinical Trial News

Nadunolimab Shows Promise in Patients with Cancer Progression After PD-1 Inhibitor Therapy

  • New data from two clinical trials reveal nadunolimab's potential in patients who have progressed on pembrolizumab treatment, a key immunotherapy.
  • The CANFOUR trial showed a 72% objective response rate in second-line NSCLC patients treated with nadunolimab plus chemotherapy after pembrolizumab failure.
  • CIRIFOUR trial data indicated a median survival of 19.7 months and a 60% disease control rate with nadunolimab and pembrolizumab in heavily pretreated patients.
  • Both studies suggest nadunolimab targets immunosuppressive cells within the tumor microenvironment, offering a new approach for overcoming immunotherapy resistance.

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

NCT05116891CompletedPhase 1
Cantargia AB
Posted 9/22/2021

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

NCT04452214CompletedPhase 1
Cantargia AB
Posted 9/24/2020

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04990037CompletedPhase 1
Cantargia AB
Posted 7/19/2021

Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.

NCT05181462Active, Not RecruitingPhase 1
Cantargia AB
Posted 1/11/2022

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

NCT03267316CompletedPhase 1
Cantargia AB
Posted 9/19/2017

Ultimovacs' UV1 Shows Promise in Mesothelioma Subgroup Analysis at ESMO 2024

  • Ultimovacs presented updated data from the Phase II NIPU trial of UV1 in combination with ipilimumab and nivolumab for mesothelioma at ESMO 2024.
  • The epithelioid subgroup, representing 70% of mesothelioma patients, showed a median PFS improvement of 5.5 months with UV1 combination therapy compared to 2.9 months with immunotherapy alone.
  • While the primary endpoint was not met, secondary endpoint analysis revealed a positive overall survival difference with UV1 treatment at the latest follow-up.
  • Ultimovacs plans to discuss these findings with key stakeholders to determine potential next steps for UV1 in addressing the unmet needs of mesothelioma patients.

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

NCT04300244Active, Not RecruitingPhase 2
Åslaug Helland
Posted 5/4/2020

C4 Therapeutics' CFT1946 Shows Promise in BRAF V600 Mutant Solid Tumors

  • C4 Therapeutics presented Phase 1 data for CFT1946, a BRAF V600 degrader, at ESMO 2024, showing a well-tolerated safety profile in patients with advanced solid tumors.
  • Early data suggests CFT1946 demonstrates dose-dependent bioavailability and successfully degrades BRAF V600E protein, indicating proof of mechanism.
  • Initial anti-tumor activity was observed, with some patients achieving partial responses and tumor reductions across various BRAF V600 mutation types.
  • The Phase 1 trial continues with expansion cohorts exploring monotherapy and combination approaches, with additional data expected in 2025.

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

NCT05668585Active, Not RecruitingPhase 1
C4 Therapeutics, Inc.
Posted 12/8/2022

Summit's Ivonescimab Demonstrates Superiority Over Keytruda in Lung Cancer Trial

  • Summit Therapeutics' ivonescimab significantly reduced the risk of lung cancer progression by 49% compared to Merck's Keytruda in a Phase 3 trial.
  • The bispecific antibody, ivonescimab, extended median progression-free survival to 11.1 months versus 5.8 months with Keytruda.
  • The HARMONi-2 trial, conducted in China, showed consistent benefits across various patient subgroups, including those with low and high PD-L1 expression.
  • While ivonescimab showed promising results, further studies, including multi-regional trials, are needed to confirm its efficacy and safety in diverse populations.

AK112 in Advanced Non-Small Cell Lung Cancer

NCT05499390Active, Not RecruitingPhase 3
Akeso
Posted 11/9/2022

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608RecruitingPhase 3
Summit Therapeutics
Posted 10/26/2023

Osimertinib and Amivantamab Gain FDA Approval for EGFR-Mutated NSCLC

  • Osimertinib receives FDA approval for unresectable Stage III EGFR-mutated NSCLC after chemoradiation, showing a significant increase in progression-free survival.
  • Amivantamab, combined with chemotherapy, gains FDA approval for EGFR exon 19 deletions or exon 21 L858R substitution mutations in NSCLC after EGFR TKI treatment.
  • Clinical trials, including LAURA and MARIPOSA-2, support these approvals, offering new targeted therapy options for patients with advanced NSCLC.

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

NCT05908734RecruitingPhase 1
Janssen Research & Development, LLC
Posted 5/18/2023

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

NCT04606381Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 11/10/2020

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428RecruitingPhase 2
Janssen Research & Development, LLC
Posted 11/11/2022

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486Active, Not RecruitingPhase 3
AstraZeneca
Posted 7/2/2019

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 12/13/2022

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 9/4/2019

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 11/17/2021

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

NCT03521154Active, Not RecruitingPhase 3
AstraZeneca
Posted 7/19/2018

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 9/30/2020

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866Active, Not RecruitingPhase 2
Janssen Research & Development, LLC
Posted 5/18/2023

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 8/5/2022

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 5/24/2016

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 10/13/2020

NeOnc Technologies Pursues Direct Listing with Intranasal Glioblastoma Therapy

  • NeOnc Technologies is pursuing a direct listing after withdrawing its IPO plans, aiming to fund development of NEO100, an intranasal drug for glioblastoma.
  • NEO100 leverages cranial nerves to bypass the blood-brain barrier, delivering perillyl alcohol (POH) directly to brain tumors, showing promise in early trials.
  • A Phase 1 study demonstrated NEO100's safety and tolerability, with some patients showing extended survival, particularly those with IDH1 mutations.
  • NeOnc's Phase 2a trial is ongoing, focusing on patients with IDH1 mutations, with preliminary data expected in mid-2025, as the company explores novel drug delivery methods.

Durvalumab Combo Shows Sustained PFS Benefit in Advanced Ovarian Cancer

  • Durvalumab plus chemotherapy and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, significantly improved progression-free survival (PFS).
  • In patients with BRCA-unmutated, HRD-positive ovarian cancer, median PFS was 45.1 months in the treatment arm versus 23.3 months in the control arm.
  • In the BRCA-unmutated ITT population, median PFS was 25.1 months for the durvalumab combination arm compared to 19.3 months for the control arm.
  • The safety profile of the durvalumab combination was consistent with previous analyses, with manageable adverse events.

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

NCT03737643Active, Not RecruitingPhase 3
AstraZeneca
Posted 1/4/2019

Multidisciplinary Long-Term Care Program Assessed for Pediatric Cancer Survivors

  • A study is underway to evaluate a structured, multidisciplinary long-term care program for pediatric cancer survivors, focusing on improving self-efficacy and overall well-being.
  • The primary outcome measured is self-efficacy, assessed using the General Self-Efficacy Scale adapted for health and healthcare contexts in patients aged 12 and older, and via proxy by parents.
  • Secondary outcomes include satisfaction with healthcare, health-related quality of life (HRQoL), mental health, and transition readiness from pediatric to adult care, utilizing validated questionnaires.
  • The trial involves at least 160 participants from ten pediatric university clinics, aiming to determine the effectiveness of the intervention compared to standard care over a 24-month recruitment period.

rTMS Shows Promise in Improving Functional Outcomes for Multiple Sclerosis Patients

  • A phase II trial is underway to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) in patients with multiple sclerosis (MS).
  • The trial utilizes the Multiple Sclerosis Functional Composite (MSFC) to measure improvements in functional outcomes after rTMS treatment.
  • Patient-reported outcome measures (PROMs) will evaluate the impact of rTMS on anxiety, depression, fatigue, quality of life, and sleep quality.
  • Advanced MRI metrics will be used to assess changes in brain lesions and tissue volume following rTMS intervention.

NEOpredict-Lung Study Shows Promising 2-Year Survival with Nivolumab Plus Relatlimab in NSCLC

  • The NEOpredict-Lung study evaluated the efficacy of nivolumab plus relatlimab in patients with resectable non-small cell lung cancer (NSCLC).
  • Two-year survival data indicates a notable proportion of patients experienced prolonged survival with the combination therapy.
  • The study provides valuable insights into the potential of immunotherapy combinations in improving outcomes for NSCLC patients.
  • Further research is warranted to validate these findings and optimize treatment strategies for this patient population.

Trending News

1

Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance One-Time Gene Editing Treatments for Cardiovascular Disease

4 days ago
2

Eli Lilly Acquires Gene-Editing Biotech Verve Therapeutics for $1.3 Billion to Expand Cholesterol Treatment Pipeline

4 days ago
3

AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint

5 days ago
4

NICE Rejects First Alzheimer's Disease-Modifying Drugs for NHS Use Due to Cost-Effectiveness Concerns

7 days ago
5

FDA Approves CSL's ANDEMBRY for Hereditary Angioedema Prevention with Novel Factor XIIa Targeting

4 days ago
6

FDA Approves Tafasitamab Triple Combination for Relapsed/Refractory Follicular Lymphoma

3 days ago
7

Samsung Biologics Expands Into Preclinical Research with Launch of Samsung Organoids Drug Screening Platform

5 days ago
8

AbbVie's Atogepant Demonstrates Superior Tolerability and Efficacy Over Topiramate in Phase 3 Migraine Prevention Trial

3 days ago
9

Draig Therapeutics Emerges from Stealth with $140M to Advance Novel Neuropsychiatric Therapies

3 days ago
10

NHS App to Feature Clinical Trial Matching System as UK Targets 150-Day Setup Times

5 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy